Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Sorry, there are no financial reports available yet.

Investor presentations

HCW Presentation September 13, 2021

ObsEva-Corporate-Deck_HCW_Final-Download

Canaccord Presentation August 12, 2021

ObsEva-Corporate-Deck_CanaccordDownload

Wedbush Presentation August 11, 2021

ObsEva_Corporate-Deck-2021-WedbushDownload

HCW Presentation March 9, 2021

ObsEva-HCW-Conference-Slides_March 9, 2021Download

SVB Leerink Presentation Feb 24, 2021

ObsEva Fireside chat_SVB Leerink_Feb 2021Download

JPM Presentation Jan 14, 2021

ObsEva_JPM Deck_1_14_2021Download

Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

P12 W52_76_10 Dec 2020Download

Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020

ObsEva_November2020presentation_jefferies 18.11Download
1 2 3

Press Releases

Annual General Meeting 2023

press release

June 8, 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a…

Read more

ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer

press release

May 2, 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2023 –…

Read more

ObsEva Annual Report 2022

press release

April 28, 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – April 28, 2023 – ObsEva SA (SIX: OBSN), a…

Read more
1 2 3 … 84

General Meetings

ObsEva Annual General Meeting 2022

May 18, 2022

Read more

ObsEva Annual General Meeting 2021

May 28, 2021

Read more
1 2 3 4

Upcoming Events

Half Year 2023 Financial Results week commencing 14 August 2023

Event


    Read more

    Annual General Meeting 2023

    Event


      Read more
       

      Stock Information

      Latest Press Release

      Annual General Meeting 2023

      Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a…

      Read more

      Investor Contact


      IR@obseva.ch

      Media Contact

      Media

      Shauna Dillon

      shauna.dillon@obseva.ch

      Contacts

      ObsEva Switzerland Office

      Chemin des Aulx,12

      1228, Plan-Les-Ouates, Geneva, Switzerland

      +41 (0)22 552 3840


      contact@obseva.ch

      Media

      Shauna Dillon

      shauna.dillon@obseva.ch

      Investor relations


      IR@obseva.ch

      Clinical studies




      clinicaltrials@obseva.ch

      HR Office

      Shauna Dillon


      shauna.dillon@obseva.ch

      CEO Office

      +41 (0)22 552 1550


      shauna.dillon@obseva.ch

       

      Sign up for news

       
       

        * Type:


        InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












        Read our privacy policy here.


         

        Are you sure you want to leave ObsEva.com?

        We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

        Continue to link

        Disclaimer

        Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

        Continue

        Disclaimer

        Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

        Continue